[1]Ottaviani G, Jaffe N.The epidemiology of osteosarcoma[J]. Cancer Treat Res, 2009, 152:3-13. [2]Gorlick R, Janeway K, Lessnick S, et al. Children's oncology group's 2013 blueprint for research: bone tumors[J]. Pediatr Blood Cancer, 2013, 60: 1009-1015. [3]Iannello A, Thompson TW, Ardolino M, et al. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells[J]. J Exp Med, 2013, 210: 2057-2069. [4]Xue W, Zender L, Miething C, et al. Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas[J]. Nature, 2007, 445: 656-660. [5]Lujambio A, Akkari L, Simon J, et al. Non-cell-autonomous tumor suppression by p53[J]. Cell, 2013, 153: 449-460. [6]Michaloglou C, Vredeveld LCW, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi[J]. Nature, 2005, 436: 720-724. [7]Rodier F, Coppé, JP, Patil C, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion[J]. Nat Cell Biol, 2009, 11: 973-979. [8]Coppé JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor [J]. Plos Biol, 2008, 6: 2853-2868. [9]Kuilman T, Michaloglou C, Vredeveld LCW, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network[J]. Cell, 2008, 133:1020-1031. [10]Christian K, Carsten G, Konstantin A, et al. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome[J]. Clin Cancer Res, 2007, 13: 2998-3005. [11]Rybak AP, Tang D. SOX2 plays a critical role in EGFR-mediated self-renewal of human prostate cancer stem-like cells[J]. Cell Signal, 2013, 25: 2734-2742. |